WT1
Wilms tumor protein
As of the edition of 20 October 2026, WT1 (wilms tumor protein, UniProt P19544) has 2 drugs tested at it and 2 companies on the list, 1 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P19544
- How well studied
- Biology documented; no tool compounds or approved drug yet
- Where it sits in the cell
- Inside the cell
- Solved structures
- 31
- Disease areas
- Cancer; Blood and lymph; Pregnancy and women's health; Urinary and reproductive; Inherited and neonatal; Hormones; Lungs and airways; Digestive system
- Registered trials of its drugs
- 11
Drugs at this target
| Status | Count |
|---|---|
| Active | 1 |
| Stopped | 1 |
| Total | 2 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Galinpepimut-s | Active | Phase 3 | none listed |
| Ombipepimut-s | Stopped | Phase 3 | none listed |
2 of 2 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 1 |
| Engaged | 1 |
| Total on the list | 2 |
| Company | Route |
|---|---|
| Sumitomo Pharma | Route A |
The other 1 company at WT1
In the product2 companies in all; 1 is not named here, and no score is.
See the 2 companies at WT1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.